HONG KONG DRUG LICENSING

Hong Kong Drug Licence FAQs

Search 500 Hong Kong drug licence FAQs on applications, personnel, premises, quality systems, ongoing regulation, renewals and acquisitions.

Information status: The original FAQ material dates from 2025 and is provided for topic-based reference; it does not represent an individual verification of all 500 FAQs against current rules. For application, fee, renewal, change, product or prescription requirements, please refer to the current official forms and guidance.

Official information from the Drug Office Official information from the Chinese Medicines Board

找到 50 条结果，第 2／3 页。每页显示 20 条；无需启用 JavaScript。

Thematic illustration for pharmaceutical licensing business queries and document organisation services — Discuss actual operating questions one-to-one to clarify the next decision.

Q471 · 什么是「1+」新药审批机制，其适用范围具体包括哪些类别的新药？独立链接

The “1+” new drug approval mechanism is an expedited approval pathway established by the Drug Office, Department of Health, to accelerate the introduction of innovative and promising new medicines to the local market. It primarily applies to innovative medicines, biologics and certain medicines for rare diseases being submitted for registration in Hong Kong for the first time. The mechanism focuses on existing approval data from internationally recognised drug regulatory authorities (such as the FDA and EMA), reducing duplicate review work and thereby shortening approval times. It does not apply to generic medicines or over-the-counter medicines already registered locally. The aim is to encourage innovative pharmaceutical companies to accelerate their expansion into overseas markets and enhance Hong Kong’s competitiveness as a regional pharmaceutical innovation hub.

📘 Regulatory basis

Section 12 of the Pharmacy and Poisons Ordinance (Cap.138), “Guidance on Registration of New Drugs” and “Details of the Fast-track Approval Pathway” issued by the Drug Office, Department of Health

📗 Drew Tang's recommendations

The applicant should ensure that complete international clinical trial data and safety information are provided, communicate with the Drug Office in advance to confirm applicability, and make full use of the accelerated benefits of the “1+” mechanism.

📕 Risk notice

If the submitted information is incomplete or falls outside the applicable scope, this may delay or even result in refusal of approval, affecting the timing of the medicine’s market launch.

Q472 · 「1+」新药审批机制对创新药企的跨境出海有何战略意义？独立链接

By simplifying the approval process and shortening the approval period, the “1+” new drug approval mechanism provides important support for innovative pharmaceutical companies seeking to obtain a drug licence in Hong Kong more quickly. As an international financial and healthcare hub, successful medicine registration in Hong Kong can serve as a springboard into the Greater China region and wider Asian markets, strengthening companies’ competitiveness. In addition, recognition of data from internationally recognised regulatory authorities helps reduce the cost of duplicate trials and improve the efficiency of new drug development. For innovative pharmaceutical companies, this means products can be commercialised earlier, cash flow optimised and global expansion strengthened, significantly improving the likelihood and speed of successful expansion into overseas markets.

📘 Regulatory basis

Section 15 of the Pharmacy and Poisons Ordinance (Cap.138), Drug Office, Department of Health, “Guidance on Strategies for Registration of New Drugs”

📗 Drew Tang's recommendations

Innovative pharmaceutical companies should leverage Hong Kong’s unique geographical and policy advantages as a regional hub and devise a registration strategy that meets the requirements of the “1+” mechanism. Prepare the international data package in advance to reduce cross-border approval barriers.

📕 Risk notice

Overlooking regulatory differences in the Hong Kong market may delay registration and affect regional marketing plans as a whole.

Q473 · 「1+」新药审批机制对申请资料的具体要求有哪些？独立链接

Under the “1+” new drug approval mechanism, applicants must submit detailed information on the medicine’s quality, safety and efficacy, giving priority to data already reviewed and approved by internationally recognised regulatory authorities such as the FDA, EMA and PMDA. This includes complete clinical trial reports, pharmacology and toxicology studies, and manufacturing process and quality control documents. Applicants must also provide detailed product information and a risk management plan. The Drug Office, Department of Health emphasises the scientific rigour and transparency of the information to ensure accurate and efficient assessment. The submitted information must be structured in accordance with the Pharmacy and Poisons Ordinance (Cap. 138) and the relevant implementing rules.

📘 Regulatory basis

Section 12 of the Pharmacy and Poisons Ordinance (Cap.138), Drug Office, “Guidance on Data for Registration of New Drugs”

📗 Drew Tang's recommendations

We recommend that applicants prepare documents strictly in accordance with international standards to avoid deficiencies. Conduct a self-check and expert pre-review in advance to ensure the scientific completeness and compliance of the materials.

📕 Risk notice

Incomplete information or insufficient data can significantly affect the progress of approval, or even result in registration failure and delay the product launch.

Q474 · 申请「1+」新药审批机制需要满足哪些具体条件？独立链接

To qualify for the “1+” new drug approval mechanism, the following conditions must be met: first, the medicine must be an innovative new drug or a drug being submitted for registration in the Hong Kong market for the first time; second, the applicant must demonstrate that the drug has been approved by at least one internationally authoritative drug regulatory authority; third, complete clinical and quality data must be submitted in accordance with local Hong Kong regulatory requirements; and finally, the applicant must have a lawful local registration representative or agent. Only applications meeting these conditions may benefit from a shortened approval timeline, priority review and other measures to improve review efficiency.

📘 Regulatory basis

Section 12 and section 15 of the Pharmacy and Poisons Ordinance (Cap.138), Drug Office, Department of Health, “Guidance on Eligibility for the Fast-track Approval Pathway”

📗 Drew Tang's recommendations

We recommend that applicants confirm in advance whether the medicine falls into an innovative category and prepare international approval documents, while ensuring that the local agent is appropriately qualified, so as not to affect eligibility to apply.

📕 Risk notice

Failure to meet the application requirements or an agent’s lack of the required qualifications may result in refusal or delay, affecting plans to launch the medicines on the market.

Q475 · 「1+」新药审批机制下，审批流程与传统审批有何不同？独立链接

Under the “1+” new drug approval mechanism, the approval process is simpler and faster than the traditional process. First, after an application is submitted, the Drug Office prioritises assigning a dedicated officer to follow it up, reducing the initial review time. Second, the mechanism allows the use of approval data from internationally authoritative bodies, reducing the need for repeated testing and review. Third, the approval period is generally shortened to within 6 months, compared with 12 months or more under the traditional process. In addition, interdepartmental coordination meetings are arranged during the approval process to resolve technical issues promptly and keep the process moving smoothly. The overall aim is to improve approval efficiency and speed up the launch of innovative medicines in Hong Kong.

📘 Regulatory basis

Section 15 of the Pharmacy and Poisons Ordinance (Cap.138), Drug Office, Department of Health, “Guidance on the Fast-track Approval Process”

📗 Drew Tang's recommendations

We recommend that applicants make full use of the advantages of the mechanism, maintain proactive communication with reviewing officers and provide supplementary information promptly to avoid approval delays caused by outdated information.

📕 Risk notice

Failure to respond promptly to feedback from the approving authority or inadequate preparation of information may result in loss of fast-track eligibility and a return to the conventional approval process.

Q476 · 「1+」新药审批机制如何处理跨境临床试验数据的认可问题？独立链接

The “1+” mechanism places emphasis on accepting international clinical trial data. Hong Kong’s Drug Office recognises results from cross-border clinical trials reviewed by internationally recognised regulatory authorities, provided that the data meet local scientific and ethical standards in Hong Kong. Applicants must provide complete reports on the trial design, conduct and results, and demonstrate compliance with the Clinical Trials Ordinance (Cap. 623) and relevant international guidelines, such as ICH-GCP. The data must also be transparent and traceable to ensure reliability. This helps reduce the need for duplicate trials and accelerate the local registration of new medicines.

📘 Regulatory basis

Clinical Trials Ordinance (Cap. 623), section 12 of the Pharmacy and Poisons Ordinance (Cap.138), Drug Office “Guidance on Acceptance of International Clinical Data”

📗 Drew Tang's recommendations

Cross-border applicants should ensure that clinical data meet Hong Kong’s ethical and regulatory standards, and consult local institutions in advance to avoid obstacles to approval due to non-compliant data.

📕 Risk notice

Using clinical data that is not recognised or does not meet the required standards may result in the information being rejected and affect the approval outcome.

Q477 · 「1+」新药审批机制对已获国际批准药品在香港的市场准入时限有何影响？独立链接

Under the ‘1+’ approval mechanism, new medicines that have already received international approval can gain access to the Hong Kong market significantly faster. The traditional approval process can take a year or longer, whereas the ‘1+’ mechanism can reduce the approval time to within 6 months, or even less. This offers considerable strategic value to innovative pharmaceutical companies seeking to enter the Hong Kong and Greater China markets quickly. Faster access can also help secure a market advantage and strengthen competitiveness, while reducing the time and capital required and enabling commercial returns to be realised sooner.

📘 Regulatory basis

Section 15 of the Pharmacy and Poisons Ordinance (Cap.138), Drug Office, “Timetable for the Fast-track Approval Pathway”

📗 Drew Tang's recommendations

We recommend that applicants prepare complete international approval documents and registration information in advance, and meet the requirements of the reviewing department to minimise the approval timeframe.

📕 Risk notice

Insufficient preparation of information or failure to respond promptly to approval comments will affect the effectiveness of expedited approval and extend the time to market.

Q478 · 「1+」新药审批机制是否适用于所有类型的创新药物？有哪些限制？独立链接

The “1+” new drug approval mechanism primarily applies to innovative medicines being registered in Hong Kong for the first time, including new chemical entities, biologics and some medicines for rare diseases. However, it does not apply to generic medicines, over-the-counter medicines or similar products already registered in the Hong Kong market. It also does not apply to medicines with significant safety concerns or without sufficient support from international certification. The mechanism is designed to focus on innovation and international recognition, ensuring that medicines approved through the expedited process have a sound basis for safety and efficacy and thereby protecting public health.

📘 Regulatory basis

Section 12 of the Pharmacy and Poisons Ordinance (Cap.138), Drug Office, Department of Health, “Scope of Application of the New Drug Fast-track Approval Mechanism”

📗 Drew Tang's recommendations

Businesses should accurately assess the innovative nature of a medicine and consult the Drug Office in advance to avoid submitting an ineligible application and incurring unnecessary time costs.

📕 Risk notice

Applying the wrong mechanism may result in the application being rejected, affecting the company’s reputation and subsequent registration process.

Q479 · 「1+」新药审批机制对药品上市后监管有何特别要求？独立链接

Although the “1+” mechanism accelerates the approval process, medicines must still comply strictly with Hong Kong's pharmaceutical regulations after they enter the market. Applicants must establish a comprehensive Risk Management Plan (RMP), submit periodic safety update reports (PSURs), and cooperate with the Drug Office in monitoring and investigating adverse drug reactions. In addition, for new medicines involving rare diseases or biological products, regulators may require post-market clinical studies to continue assessing safety and efficacy. Strict post-market regulation helps ensure public safety in the use of medicines while safeguarding product quality and the company's reputation.

📘 Regulatory basis

Section 16 of the Pharmacy and Poisons Ordinance (Cap.138), Drug Office, “Guidance on Post-marketing Management of Medicines”

📗 Drew Tang's recommendations

We recommend that businesses establish a professional pharmacovigilance team, strictly fulfil post-market monitoring obligations and respond promptly to regulatory requests.

📕 Risk notice

Failure to fulfil post-market surveillance obligations may result in fines, licence revocation or legal liability, seriously affecting the company’s long-term development.

Q480 · 「1+」新药审批机制是否支持跨境合作研发药物的注册申请？独立链接

The “1+” new drug approval mechanism supports registration applications for innovative medicines developed through cross-border collaboration. Applicants may submit clinical and registration data from partners in other countries or regions and draw on internationally recognised data to accelerate the approval process. The mechanism also encourages cross-border data sharing and regulatory coordination, simplifying the acceptance of clinical trial data from multiple countries and supporting the global development of innovative medicines. Companies must ensure that collaboration agreements clearly define data ownership and the allocation of responsibilities, and comply with Hong Kong’s regulatory requirements to safeguard the completeness and lawfulness of the application materials.

📘 Regulatory basis

Section 12 of the Pharmacy and Poisons Ordinance (Cap.138), Drug Office, Department of Health, “Guidance on Registration of Medicines under Cross-border Collaboration”

📗 Drew Tang's recommendations

We recommend that both parties to cross-border cooperation establish comprehensive document-management and communication mechanisms to ensure documents remain compliant and are updated promptly, helping facilitate approval.

📕 Risk notice

Inconsistent cross-border information or unclear legal responsibilities may give rise to disputes during approval, affecting registration progress and subsequent market access.

Q481 · 申请香港药品进出口许可证需要满足哪些主要条件？独立链接

Under section 20 of the Pharmacy and Poisons Ordinance (Cap. 138), applicants for an import or export licence must hold a valid pharmaceutical licence and ensure that imported or exported medicines comply with Hong Kong’s quality and safety standards. Applicants must submit detailed information about the goods, the import or export destination and intended use, and must also have appropriate storage and transport conditions. The Drug Office, Department of Health will rigorously review the application documents to ensure compliance with the requirements for the regulation of medicines. Rengangyongsheng (Hong Kong) Limited recommends preparing all supporting documents in advance to avoid approval delays due to incomplete information.

📘 Regulatory basis

Section 20 of the Pharmacy and Poisons Ordinance (Cap.138); relevant Department of Health Drug Office guidance

📗 Drew Tang's recommendations

Be sure to prepare detailed medicine information and evidence of compliance, and communicate with the Department of Health in advance to improve approval efficiency.

📕 Risk notice

Inconsistent information or failure to hold a valid licence may result in the application being refused and may even lead to fines or criminal liability.

Q482 · 跨境电商平台如天猫国际销售药品，香港卖家需要具备哪些资质？独立链接

Hong Kong sellers using cross-border e-commerce platforms such as Tmall Global to sell medicines must hold the relevant Hong Kong pharmaceutical licences and obtain the corresponding import and export licences. Under sections 18 and 20 of the Pharmacy and Poisons Ordinance (Cap. 138), sales of regulated medicines must comply with the applicable requirements and use lawful sales channels. Platforms will also require sellers to provide proof of their qualifications. Rengangyongsheng (Hong Kong) Limited recommends that sellers consult the platform and the Hong Kong Department of Health in advance to ensure that all necessary qualifications are in place and avoid the risks of non-compliant sales.

📘 Regulatory basis

Sections 18 and 20 of the Pharmacy and Poisons Ordinance (Cap.138); relevant cross-border sales rules of Tmall Global

📗 Drew Tang's recommendations

We recommend that sellers ensure they have the necessary medicine licences and import/export permits, and maintain communication with the platform's compliance team to avoid missing qualifications

📕 Risk notice

Selling medicines without the required qualifications may result in a platform ban and even enforcement action by Hong Kong regulatory authorities.

Q483 · 进出口许可证的申请流程一般需要多长时间？独立链接

According to the requirements of the Drug Office, Department of Health, import and export licence applications generally take around 6 to 8 working days to process after complete information has been submitted. Processing may take longer if information is incomplete or special categories of medicines are involved. Applicants should prepare detailed medicine information, evidence of the purpose of import or export, and the relevant licences in advance. Rengangyongsheng (Hong Kong) Limited recommends starting the application 1 month in advance and maintaining communication with the Department of Health during this period to ensure that any additional information is submitted promptly and business operations are not delayed.

📘 Regulatory basis

Drug Office, Department of Health: Application process and indicative timelines for import and export licences

📗 Drew Tang's recommendations

Prepare complete documentation in advance and plan the schedule appropriately to avoid delays to goods movement caused by approval delays.

📕 Risk notice

Incomplete information or insufficient qualifications will extend the approval process and affect the fulfilment of commercial contracts.

Q484 · 通过京东健康等平台销售香港注册药品，需要办理哪些香港药牌？独立链接

To sell medicines on JD Health in Hong Kong, sellers must hold a Hong Kong pharmaceutical licence and the relevant import and export licences. Under the Pharmacy and Poisons Ordinance (Cap. 138), additional licences are required for prescription medicines or controlled medicines. For non-prescription medicines, sellers must ensure that the medicines are registered in Hong Kong or meet the applicable listing requirements. Rengangyongsheng recommends that sellers identify the appropriate licence category based on the types of medicines they intend to sell and confirm the compliance requirements with the platform, to ensure that their sales activities are lawful and compliant.

📘 Regulatory basis

Section 18 of the Pharmacy and Poisons Ordinance (Cap.138); Department of Health rules for registered medicines

📗 Drew Tang's recommendations

Obtain the appropriate drug licence according to the category of medicine to avoid penalties for selling unregistered medicines

📕 Risk notice

Selling without a pharmaceutical licence or selling unregistered medicines may result in administrative penalties and the products being removed from platforms.

Q485 · 香港药品进出口许可证是否支持跨境电商直接使用？独立链接

Hong Kong import and export licences for medicines mainly apply to the import and export trade in physical goods. Cross-border e-commerce involves online transactions and delivery, and must still comply with the relevant medicine sales and advertising regulations. Cross-border e-commerce sellers must ensure that they hold valid pharmaceutical trade and import and export licences, and that the medicines sold meet Hong Kong’s registration and labelling requirements. Rengangyongsheng (Hong Kong) Limited advises that cross-border e-commerce businesses take platform rules and Hong Kong regulations into account and use import and export licences appropriately and compliantly, to avoid compliance risks arising from differences in online sales models.

📘 Regulatory basis

Sections 18 and 20 of the Pharmacy and Poisons Ordinance (Cap.138); Department of Health guidance on cross-border e-commerce regulation

📗 Drew Tang's recommendations

Cross-border e-commerce sellers should comprehensively assess online and offline compliance requirements and ensure that licences cover every stage of sales

📕 Risk notice

Misusing permits or overlooking online sales compliance may result in regulatory penalties and damage to your reputation.

Q486 · 申请进出口许可证时，是否需要提供药品的注册证明？独立链接

Yes, when applying for a Hong Kong medicine import/export licence, you must submit proof of medicine registration or evidence that the product may lawfully be sold in the importing country. Under section 20 of the Pharmacy and Poisons Ordinance (Cap. 138), the Drug Office, Department of Health requires confirmation that the medicine has a lawful source and meets quality standards. If the medicine is not yet registered in Hong Kong, relevant clinical or quality data must be provided in support of the application. Rengangyongsheng (Hong Kong) Limited recommends preparing a complete set of registration documents in advance to help ensure a smooth assessment.

📘 Regulatory basis

Section 20 of the Pharmacy and Poisons Ordinance (Cap.138); Department of Health Drug Office registration and import requirements

📗 Drew Tang's recommendations

Prepare product registration or proof of lawful sale in advance to avoid refusal due to insufficient documentation.

📕 Risk notice

Lack of valid proof may delay or invalidate a licence, affecting business operations.

Q487 · 跨境电商销售中，香港卖家如何确保其药品广告符合本地法规？独立链接

Under section 38 of the Pharmacy and Poisons Ordinance (Cap. 138), advertisements for medicines must not contain false or misleading content or promote unapproved therapeutic claims. Cross-border e-commerce sellers must ensure that all advertising complies with the requirements of the Hong Kong Drug Office and must not directly or indirectly promote prescription medicines to the public. Rengangyongsheng (Hong Kong) Limited recommends that sellers work with a professional compliance team to review advertising content and ensure that promotional copy meets regulatory requirements, avoiding regulatory penalties for non-compliant advertising.

📘 Regulatory basis

Section 38 of the Pharmacy and Poisons Ordinance (Cap.138); Department of Health Code of Practice on Drug Advertising

📗 Drew Tang's recommendations

Review advertisements for compliance before publication, paying particular attention to the prohibition on promoting the efficacy of prescription medicines

📕 Risk notice

Non-compliant advertising may lead to fines, licence revocation and removal from platforms.

Q488 · 香港药剂业许可证和进出口许可证是否可由同一家公司申请？独立链接

Yes. Under the Pharmacy and Poisons Ordinance (Cap. 138), the pharmaceutical licence and import/export licences may be applied for and held by the same corporate entity. The licence holder must meet the relevant requirements for facilities, personnel qualifications and management, and ensure that the storage, transport and sale of medicines comply with the law. Rengangyongsheng (Hong Kong) Limited recommends that businesses consolidate their application processes and manage compliance centrally, which can help improve operational efficiency and reduce regulatory risks.

📘 Regulatory basis

Sections 17 and 20 of the Pharmacy and Poisons Ordinance (Cap.138)

📗 Drew Tang's recommendations

Holding two licences in the same company can simplify management; business structures should be planned appropriately.

📕 Risk notice

Misuse of a licence or operating beyond its scope may lead to enforcement risks

Q489 · 跨境电商销售药品时，香港卖家是否需要额外申请网络销售许可？独立链接

Hong Kong legislation does not currently establish a separate licence specifically for online medicine sales. However, under the Pharmacy and Poisons Ordinance (Cap.138), any medicine sales activity must be covered by a valid pharmacy licence and the relevant import and export licences. Online sales are subject to the same regulatory requirements as other sales channels. Rengangyongsheng advises sellers to ensure their existing licences cover all sales channels before undertaking cross-border e-commerce, and to monitor the latest Department of Health policies.

📘 Regulatory basis

Section 18 of the Pharmacy and Poisons Ordinance (Cap.138); Department of Health guidance on online sales

📗 Drew Tang's recommendations

Confirm that the existing licence covers online sales, monitor policy changes closely and avoid compliance blind spots.

📕 Risk notice

Failure to cover online sales channels may result in non-compliant operations and risk of penalties

Q490 · 如何处理跨境电商平台要求的香港药品进出口资质审查？独立链接

Cross-border e-commerce platforms generally require sellers to provide Hong Kong pharmaceutical licences and import and export licences as evidence of their legal eligibility to sell medicines. Sellers should prepare all required qualification documents, including pharmaceutical licences, import and export licences and product registration certificates, and proactively cooperate with the platform’s qualification review process. Rengangyongsheng (Hong Kong) Limited recommends establishing a standardised qualification management system to ensure that documents are accurate, valid and updated promptly in response to platform requirements, thereby improving the prospects for successful cooperation and the level of business compliance.

📘 Regulatory basis

Pharmacy and Poisons Ordinance (Cap.138); qualification requirements for cross-border e-commerce platforms

📗 Drew Tang's recommendations

Maintain complete qualification records and proactively cooperate with platform reviews to avoid delays to sales caused by qualification checks

📕 Risk notice

Insufficient qualifications or false information may lead the platform to refuse to work with you, affecting business development.

Hong Kong Drug Licence FAQs

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang